Advertisement

Related Videos

Ian Tannock, MD, PhD, DSc, on Near-Equivalence: A Better Question Than Non-Inferiority

Cody Peer, PhD, on Simulating Alternative Schedules for Checkpoint Inhibitors

Mark Sculpher, PhD: How Do We Assess the Value of Cancer Drug Optimization?

Welcome and Introduction to Vi3C

Peter Clark, MA, MD, FRCP: A Payer Perspective

Advertisement

Advertisement




Sep
02
Today In Oncology
Radiation to the Thymus in NSCLC Treatment May Increase Risk of Metastasis
Osimertinib Plus Chemotherapy Significantly Extends Progression-Free Survival in EGFR/TP53-Mutated NSCLC
Two Studies Build Evidence Supporting the Use of ctDNA as an Early Endpoint
The 2026 ASCO Annual Meeting Geriatric Oncology Update: The Next Challenge Is Implementation
Researchers Identify Donor NK Cell Subset That Impairs CAR NK Cell Therapy and Demonstrate a Manufacturing Solution
View More 
Advertisement
© 2026 HSP News Service, L.L.C.
Conexiant Oncology Logo